Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 75
Filtrar
1.
Int J Biol Macromol ; 269(Pt 2): 132169, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38723801

RESUMO

In our study, we developed a point of care electrochemical biosensing platform based on the functionalized cysteine-positioned gold electrode to diagnose yellow fever disease from human plasma samples. The developed platform underwent characterization through diverse methods encompassing cyclic voltammetry, electrochemical impedance spectroscopy, scanning electron microscopy, energy dispersive X-ray spectroscopy, and density-functional theory. The capacitive interaction between yellow fever virus non-structural antigen and antibody gave a cathodic signal at approximately -260 mV, and increased in proportion to the amount of non-structural antibody. The created electrochemical biosensor has an ability to detect 96 ag/mL of the yellow fever non-structural antibody with an extensive analytical range varied from 0.1 fg/mL to 1 µg/mL. The interference effects of various substances that could be found in human plasma, and the performance of the method were examined from the point of recovery and relative standard deviation for human plasma samples; hereby, the results confirmed the unprecedented selectivity and accuracy of the proposed method.


Assuntos
Técnicas Biossensoriais , Técnicas Eletroquímicas , Proteínas não Estruturais Virais , Febre Amarela , Humanos , Técnicas Biossensoriais/métodos , Febre Amarela/diagnóstico , Febre Amarela/sangue , Febre Amarela/imunologia , Febre Amarela/virologia , Proteínas não Estruturais Virais/imunologia , Proteínas não Estruturais Virais/sangue , Técnicas Eletroquímicas/métodos , Sistemas Automatizados de Assistência Junto ao Leito , Vírus da Febre Amarela/imunologia , Teoria da Densidade Funcional , Eletrodos , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Ouro/química
4.
Rev. saúde pública (Online) ; 57: 46, 2023. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1450396

RESUMO

ABSTRACT OBJECTIVE To evaluate the accuracy of yellow fever (YF) suspected case definitions from the Brazilian Ministry of Health (BMH) and World Health Organization (WHO), as well as propose and evaluate new definitions of suspected cases, considering confirmed and discarded cases. METHODS The retrospective study was conducted at the Instituto de Infectologia Emílio Ribas (IIER), using the Epidemiologic Surveillance Form of YF cases. From the confirmed and discarded cases of YF, a logistic regression model was developed. The independent variables were used in a proposed definition of a suspected case of YF and its accuracy was evaluated. RESULTS In total, 113 YF suspect cases were reported, with 78 confirmed (69.0%). The definitions by BMH and WHO presented low sensitivity, 59% and 53.8%, and reduced accuracy, 53.1% and 47.8%, respectively. Predictive factors for YF were thrombocytopenia, leukopenia, and elevation of transaminases greater than twice normal. The definition including individual with acute onset of fever, followed by elevation of ALT or AST greater than twice the reference value AND leukopenia OR thrombocytopenia presented high sensitivity (88.3%), specificity (62.9%), and the best accuracy (80.4%), as proposed in the model. CONCLUSION The YF suspected case definitions of the BMH and the WHO have low sensitivity. The inclusion of nonspecific laboratory tests increases the accuracy of YF definition.


Assuntos
Humanos , Masculino , Febre Amarela/diagnóstico , Febre Amarela/epidemiologia , Relatos de Casos , Monitoramento Epidemiológico , Confiabilidade dos Dados
5.
Bol. malariol. salud ambient ; 62(5): 976-983, 2022. tab
Artigo em Espanhol | LILACS, LIVECS | ID: biblio-1427005

RESUMO

En los centros de Emergencia con poco apoyo de laboratorio, es difícil diferenciar a los pacientes con dengue grave y fiebre amarilla severa. El objetivo fue comparar el perfil clínico y de laboratorio de los pacientes con dengue grave y fiebre amarilla severa en Urgencias. Se realizó un estudio observacional retrospectivo de pacientes con diagnóstico confirmado de dengue y fiebre amarilla en el período 2018 a 2020 atendidos en la Unidad de Emergencia del Hospital Carrión, Huancayo-Perú. Se evaluaron un total de 35 pacientes, 11 pacientes (31,4%) fueron diagnosticados con fiebre amarilla severa y 24 pacientes (68,5%) con dengue grave. La media de los resultados de laboratorio con fiebre amarilla severa fueron bilirrubina indirecta 4,7 ml/dL, aspartato transaminasa 4463 UI/L, transaminasa aminotransferasa 4329 UI/L, creatinina 4,9 mg/dl. En pacientes con dengue grave el hematocrito promedio fue 51,8, hemoglobina 17,6 g/dl, plaquetas 24 × 103/mm. En pacientes con síndrome ictérico-febril la presencia de bradicardia, bilirrubina indirecta elevada y transaminasas muy elevadas debe hacer sospechar de fiebre amarilla; mientras que los pacientes que acuden por ascitis, derrame pleural, aumento de hematocrito y deficiencia de plaquetas, se debe tratar como dengue grave sobre todo en Unidades de Emergencia con poco apoyo de laboratorio(AU)


In Emergency centers with little laboratory support, differentiating patients with dengue and yellow fever is difficult. The Aim was to compare the clinical and laboratory profile of patients with severe dengue and severe yellow fever in the Emergency unit. We conducted a retrospective observational study of patients with a confirmed diagnosis of dengue and yellow fever in the period 2018 to 2020 treated in the Emergency Unit of the Carrión hospital, Huancayo-Peru. A total of 35 patients were evaluated, 11 patients (31.4%) were diagnosed with severe yellow fever and 24 patients (68.5%) with severe dengue. The mean laboratory results in patients with severe yellow fever were indirect bilirubin 4.7 ml/dL, aspartate transaminase 4463 IU/L, transaminase aminotransferase 4329 IU/L, creatinine 4.9 mg / dl. In patients with severe dengue were hematocrit 51.8, hemoglobin 17.6 g / dl, platelets 24 × 103 / mm. In patients with syndrome jaundice and fever the presence of bradycardia, elevated indirect bilirubin, and very elevated transaminases should be suspicious for yellow fever; while in patients who come for ascites, pleural effusion, increased hematocrit and platelet deficiency, it should be treated as severe dengue especially in Emergency Units with little laboratory support(AU)


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Febre Amarela/diagnóstico , Dengue Grave/diagnóstico , Testes de Química Clínica , Hematologia , Bilirrubina/análise , Plaquetas , Hemoglobinas , Creatina/análise
6.
Talanta ; 208: 120338, 2020 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-31816752

RESUMO

Arboviruses have been emerging as a significant global health problem due to the recurrent epidemics. Arboviruses require the development of new diagnostic devices due to the nonspecific clinical manifestations. Herein, we report a biosensor based on cysteine (Cys), zinc oxide nanoparticles (ZnONp), and Concanavalin A (ConA) lectin to differentiate between arboviruses infections. ConA is capable of interacting with the saccharide components of the viral capsid. In this study, we evaluated the reproducibility, sensitivity, and specificity of the sensor for the virus of Dengue type 2 (DENV2), Zika (ZIKV), Chikungunya (CHIKV), and Yellow fever (YFV). Atomic force microscopy measurements confirmed the electrode surface modification and revealed a heterogeneous topography during the biorecognition process. Cyclic voltammetry (CV) and impedance spectroscopy (EIS) were used to characterize the biosensor. The blockage of the oxidation-reduction process is related to the formation of Cys-ZnONp-ConA system on the electroactive area and its subsequent interaction with viral glycoproteins. The sensor exhibited a linear response to different concentrations of the studied arboviruses. Our study demonstrates that ConA lectin recognizes the structural glycoproteins of the DENV2, ZIKV, CHIKV, and YFV. DENV2 is the most structurally similar to ZIKV. Our results have shown that the impedimetric response correlates with the structural glycoproteins, as follow: DENV2 (18.6 kΩ) > ZIKV (14.6 kΩ) > CHIKV (6.86 kΩ) > YFV (5.98 kΩ). The homologous structural regions contribute to ConA-arboviruses recognition. Our results demonstrate the use of the proposed system for the development of biosensors for arboviruses infections.


Assuntos
Infecções por Arbovirus/diagnóstico , Arbovírus/metabolismo , Técnicas Biossensoriais/métodos , Concanavalina A/química , Eletroquímica/métodos , Eletrodos , Nanopartículas Metálicas/química , Infecções por Arbovirus/sangue , Infecções por Arbovirus/virologia , Arbovírus/isolamento & purificação , Febre de Chikungunya/sangue , Febre de Chikungunya/diagnóstico , Febre de Chikungunya/virologia , Vírus Chikungunya/isolamento & purificação , Vírus Chikungunya/metabolismo , Cisteína/química , Dengue/sangue , Dengue/diagnóstico , Dengue/virologia , Vírus da Dengue/isolamento & purificação , Vírus da Dengue/metabolismo , Diagnóstico Diferencial , Glucose/análise , Humanos , Manose/análise , Febre Amarela/sangue , Febre Amarela/diagnóstico , Febre Amarela/virologia , Vírus da Febre Amarela/isolamento & purificação , Vírus da Febre Amarela/metabolismo , Zika virus/isolamento & purificação , Zika virus/metabolismo , Infecção por Zika virus/sangue , Infecção por Zika virus/diagnóstico , Infecção por Zika virus/virologia , Óxido de Zinco/química
7.
Mem. Inst. Oswaldo Cruz ; 115: e190501, 2020. graf
Artigo em Inglês | LILACS, Sec. Est. Saúde SP | ID: biblio-1135279

RESUMO

BACKGROUND Non-human primates contribute to the spread of the yellow fever virus (YFV) and the establishment of transmission cycles in endemic areas. OBJECTIVE To describe the severe histopathological aspects of YFV infection, 10 squirrel monkeys were infected with YFV and blood, brain, liver, kidney, spleen, heart, lung, lymph node and stomach were collected at 1-7, 10, 20 and 30 days post-infection (dpi). METHODS Histopathological analysis and detection of the genome and viral antigens and neutralising antibodies were performed by RT-PCR, immunohistochemistry and neutralisation test, respectively. FINDINGS Only one animal died from the experimental infection. The genome and viral antigens were detected in all investigated organs (1-30 dpi) and the neutralising antibodies from seven to 30 dpi. The brain contained perivascular haemorrhage (6 dpi); in the liver, midzonal haemorrhage and lytic necrosis (6 dpi) were observed. The kidney had bleeding in the Bowman's capsule and tubular necrosis (6 dpi). Pyknotic lymphocytes were observed in the spleen (1-20 dpi), the lung had haemorrhage (2-6 dpi), in the endocardium it contained nuclear pyknosis and necrosis (2-3 dpi) and the stomach contained blood in the lumen (6 dpi). MAIN FINDINGS Squirrel monkeys reliably reproduced the responses observed in human cases of yellow fever and, therefore, constitute an excellent experimental model for studies on the pathophysiology of the disease.


Assuntos
Animais , Saimiri/virologia , Febre Amarela/diagnóstico , Vírus da Febre Amarela/isolamento & purificação , Modelos Animais de Doenças
8.
Rev. peru. med. exp. salud publica ; 36(4): 700-704, oct.-dic. 2019. tab, graf
Artigo em Espanhol | LILACS | ID: biblio-1058789

RESUMO

RESUMEN Fiebre amarilla (FA) y leptospirosis son zoonosis endémicas subdiagnosticadas de las regiones tropicales de África y Sudamérica. Ambas, pueden ser clínicamente indistinguibles y presentarse como síndrome febril icterohemorrágico agudo. Reportamos el caso de un varón de 20 años, procedente del departamento de Amazonas que se presentó con nueve días de enfermedad caracterizada por falla multiorgánica (compromiso neurológico, renal, hepático, respiratorio, y hematológico). Recibió tratamiento antibiótico, soporte transfusional, dialítico, hemodinámico, y ventilatorio; y a pesar de la gravedad del cuadro clínico, evolucionó favorablemente. Se confirmó FA por Rt-PCR y se obtuvo serología positiva para leptospira por ELISA y microaglutinación. Sin embargo, no se pudo demostrar, desde el punto de vista laboratorial, coinfección real por FA y leptospira. Este caso de FA severa con desenlace no fatal enfatiza la importancia del diagnóstico sindrómico adecuado, y un tratamiento de soporte precoz y agresivo que puede salvar la vida del paciente.


ABSTRACT Yellow fever (YF) and leptospirosis are under-diagnosed endemic zoonoses of the tropical regions of Africa and South America. Both may be clinically indistinguishable and present as an acute icterohemorrhagic febrile syndrome. We report the case of a 20-year-old male from the department of Amazonas who presented with nine days of disease characterized by multiorgan failure (neurological, renal, hepatic, respiratory, and hematological involvement). He received antibiotic treatment, as well as, transfusion, dialysis, hemodynamic, and ventilatory support. Despite the severity of the clinical condition, he evolved favorably. YF was confirmed by Rt-PCR and positive serology was obtained for leptospira by ELISA and microagglutination. However, from a laboratory point of view, real co-infection by yellow fever and leptospira could not be demonstrated. This case of severe YF with non-fatal outcome emphasizes the importance of adequate syndromic diagnosis, and early and aggressive supportive treatment that can save a patient's life.


Assuntos
Animais , Humanos , Masculino , Adulto Jovem , Febre Amarela , Febre , Leptospirose , Peru , Febre Amarela/diagnóstico , Febre Amarela/terapia , Índice de Gravidade de Doença , Zoonoses/diagnóstico , Zoonoses/terapia , Febre/etiologia , Coinfecção , Leptospirose/diagnóstico , Leptospirose/terapia
9.
Emerg Infect Dis ; 25(6): 1248-1249, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30870138

RESUMO

In 2018, yellow fever with hepatitis was diagnosed for 2 unvaccinated travelers returning to France from Brazil. Hepatitis persisted for >6 months; liver enzyme levels again increased 2 months after disease onset with no detection of yellow fever virus RNA or other pathogens. Persistent hepatitis with hepatic cytolysis rebound probably resulted from immune response.


Assuntos
Hepatite/epidemiologia , Febre Amarela/epidemiologia , Vírus da Febre Amarela , Biópsia , Brasil/epidemiologia , Comorbidade , Hepatite/diagnóstico , Hepatite/etiologia , Humanos , Testes de Função Hepática , Vigilância em Saúde Pública , Febre Amarela/diagnóstico , Febre Amarela/virologia
10.
Rev. bras. anal. clin ; 51(1): 25-28, 30/03/2019. tab
Artigo em Português | LILACS | ID: biblio-1008146

RESUMO

A Febre Amarela é uma doença infecciosa aguda, caracterizada por febre. Não é transmissível e tem duração de no máximo 12 dias. As manifestações clínicas revelam as fases evolutivas da doença. Este trabalho consiste em um artigo de atualização, no qual foi realizado um estudo bibliográfico interpretativo e descritivo baseado na literatura atual sobre a Febre Amarela no Brasil. Esta doença é causada por um arbovírus que pertence à família Flaviviridae. A expansão da área de vacinação é muito discutida atualmente. Segundo o Ministério da Saúde, em 2016, foram confirmados seis casos de Febre Amarela no Brasil. Conforme a Sociedade Brasileira de Infectologia, a fisiopatologia desta doença é a mesma no ciclo urbano e no silvestre. O seu diagnóstico pode ser dividido em clínico e laboratorial, pois são as duas formas de confirmar a doença em indivíduos. As medidas preventivas consistem, principalmente, na imunização, medidas de proteção e no controle do vetor. Esta pesquisa fornece dados atuais em bases confiáveis, podendo ser utilizada para futuros trabalhos.


Yellow Fever is an acute infectious disease, characterized by fever. It is not transferable and lasts for a maximum of 12 days. The clinical manifestations reveal the evolutionary phases of the disease. This work consists of an update article, where an interpretative and descriptive bibliographic study was carried out based on the current literature on Yellow Fever in Brazil. This disease is caused by an arbovirus belonging to the family Flaviviridae. The expansion of the vaccination area is much discussed today. According to the Ministry of Health, in 2016, six cases of yellow fever were confirmed in Brazil. According to the Brazilian Society of Infectology, the pathophysiology of Yellow Fever is the same in the urban and wild cycle. The diagnosis of yellow fever can be divided into clinical and laboratory, as they are the two ways to confirm the disease in individuals. Preventive measures consist mainly of immunization, protective measures and vector control. This research provides current data on a reliable basis and can be used for future work


Assuntos
Febre Amarela/diagnóstico , Febre Amarela/etiologia , Febre Amarela/epidemiologia , Febre Amarela/fisiopatologia , Febre Amarela/prevenção & controle , Febre Amarela/terapia , Aedes
11.
Rev Assoc Med Bras (1992) ; 64(2): 106-113, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29641667

RESUMO

The yellow fever (YF) virus is a Flavivirus, transmitted by Haemagogus, Sabethes or Aedes aegypti mosquitoes. The disease is endemic in forest areas in Africa and Latin America leading to epizootics in monkeys that constitute the reservoir of the disease. There are two forms of YF: sylvatic, transmitted accidentally when approaching the forests, and urban, which can be perpetuated by Aedes aegypti. In Brazil, the last case of urban YF occurred in 1942. Since then, there has been an expansion of transmission areas from the North and Midwest regions to the South and Southeast. In 2017, the country faced an important outbreak of the disease mainly in the states of Minas Gerais, Espírito Santo and Rio de Janeiro. In 2018, its reach extended from Minas Gerais toward São Paulo. Yellow fever has an incubation period of 3 to 6 days and sudden onset of symptoms with high fever, myalgia, headache, nausea/vomiting and increased transaminases. The disease ranges from asymptomatic to severe forms. The most serious forms occur in around 15% of those infected, with high lethality rates. These forms lead to renal, hepatic and neurological impairment, and bleeding episodes. Treatment of mild and moderate forms is symptomatic, while severe and malignant forms depend on intensive care. Prevention is achieved by administering the vaccine, which is an effective (immunogenicity at 90-98%) and safe (0.4 severe events per 100,000 doses) measure. In 2018, the first transplants in the world due to YF were performed. There is also an attempt to evaluate the use of active drugs against the virus in order to reduce disease severity.


Assuntos
Aedes , Insetos Vetores , Febre Amarela , Animais , Brasil/epidemiologia , Surtos de Doenças/prevenção & controle , Humanos , Febre Amarela/diagnóstico , Febre Amarela/epidemiologia , Febre Amarela/prevenção & controle , Febre Amarela/transmissão , Vacina contra Febre Amarela/normas
12.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 64(2): 106-113, Feb. 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1041014

RESUMO

Summary The yellow fever (YF) virus is a Flavivirus, transmitted by Haemagogus, Sabethes or Aedes aegypti mosquitoes. The disease is endemic in forest areas in Africa and Latin America leading to epizootics in monkeys that constitute the reservoir of the disease. There are two forms of YF: sylvatic, transmitted accidentally when approaching the forests, and urban, which can be perpetuated by Aedes aegypti. In Brazil, the last case of urban YF occurred in 1942. Since then, there has been an expansion of transmission areas from the North and Midwest regions to the South and Southeast. In 2017, the country faced an important outbreak of the disease mainly in the states of Minas Gerais, Espírito Santo and Rio de Janeiro. In 2018, its reach extended from Minas Gerais toward São Paulo. Yellow fever has an incubation period of 3 to 6 days and sudden onset of symptoms with high fever, myalgia, headache, nausea/vomiting and increased transaminases. The disease ranges from asymptomatic to severe forms. The most serious forms occur in around 15% of those infected, with high lethality rates. These forms lead to renal, hepatic and neurological impairment, and bleeding episodes. Treatment of mild and moderate forms is symptomatic, while severe and malignant forms depend on intensive care. Prevention is achieved by administering the vaccine, which is an effective (immunogenicity at 90-98%) and safe (0.4 severe events per 100,000 doses) measure. In 2018, the first transplants in the world due to YF were performed. There is also an attempt to evaluate the use of active drugs against the virus in order to reduce disease severity.


Assuntos
Humanos , Animais , Febre Amarela/diagnóstico , Febre Amarela/prevenção & controle , Febre Amarela/transmissão , Febre Amarela/epidemiologia , Aedes , Insetos Vetores , Brasil/epidemiologia , Surtos de Doenças/prevenção & controle , Vacina contra Febre Amarela/normas
14.
Mem. Inst. Oswaldo Cruz ; 113(10): e180278, 2018. graf
Artigo em Inglês | LILACS | ID: biblio-955108

RESUMO

We discuss the complex eco-social factors involved in the puzzle of the unexpected rapid viral spread in the ongoing Brazilian yellow fever (YF) outbreak, which has increased the reurbanisation risk of a disease without urban cases in Brazil since 1942. Indeed, this rapid spatial viral dissemination to the Southeast and South regions, now circulating in the Atlantic Forest fragments close to peri-urban areas of the main Brazilian megalopolises (São Paulo and Rio de Janeiro) has led to an exponential increase in the number of yellow fever cases. In less than 18 months, 1,833 confirmed cases and 578 deaths were recorded most of them reported in the Southeast region (99,9%). Large epizooties in monkeys and other non-human primates (NHPs) were communicated in the country with 732 YF virus (YFV) laboratory confirmed events only in the 2017/2018 monitoring period. We also discuss the peculiarities and similarities of the current outbreak when compared with previous great epidemics, examining several hypotheses to explain the recent unexpected acceleration of epizootic waves in the sylvatic cycle of the YFV together with the role of human, NHPs and mosquito mobility with respect to viral spread. We conclude that the most feasible hypothesis to explain this rapidity would be related to human behavior combined with ecological changes that promoted a significant increase in mosquito and NHP densities and their contacts with humans. We emphasize the urgent need for an adequate response to this outbreak such as extending immunisation coverage to the whole Brazilian population and developing novel strategies for immunisation of NHPs confined in selected reserve areas and zoos. Finally, we stress the urgent need to improve the quality of response in order to prevent future outbreaks and a catastrophic reurbanisation of the disease in Brazil and other South American countries. Continuous monitoring of YFV receptivity and vulnerability conditions with effective control of the urban vector Aedes aegypti and significant investments in YF vaccine production capacity and research and development for reduction of adverse effects are of the highest priority.


Assuntos
Humanos , Febre Amarela/diagnóstico , Febre Amarela/terapia , Febre Amarela/transmissão , Imunização/métodos , Aedes
15.
Artigo em Inglês | LILACS | ID: biblio-964195

RESUMO

The aim of the present study was to describe an improved protocol of reverse transcription polymerase chain reaction (RT-PCR) for Yellow Fever virus genome detection. A strain of ribonucleic acid of Yellow Fever virus was submitted to the improved protocol of RT-PCR and the amplicons were visualized under ultraviolet transilluminator, purifed and sequenced. The nucleotide sequence obtained was compared with sequences available in GenBank using the tblastx tool. The amplicons produced by the strain of ribonucleic acid of Yellow Fever virus exhibited fragments of 400 and 800 base pairs and the consensus sequence exhibited a similarity of 100% with Yellow Fever virus sequences recorded in GenBank. The improved protocol described in this study allowed Yellow Fever virus genome detection and enabled the elimination of the nested-PCR step, which has been frequently associated with contamination. In addition, it reduced the time of reaction, the cost of reagents and the possibility of sample contamination. New methods of investigating these infections must be elaborated and a continuous vigilance of these viruses in their different vectors and hosts is required to avoid negative impacts on human health, tourism and trade.(AU)


Assuntos
Humanos , Animais , Febre Amarela/diagnóstico , Febre Amarela/virologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa/instrumentação , Flavivirus/isolamento & purificação , Infecções por Flavivirus/diagnóstico , Flavivirus/genética
16.
BMJ Case Rep ; 20162016 Aug 29.
Artigo em Inglês | MEDLINE | ID: mdl-27571912

RESUMO

We present a case of a 56-year-old woman with Crohn's disease, treated with methotrexate and infliximab, who inadvertently received yellow fever vaccination (YFV) prior to a journey to Tanzania. She was not previously vaccinated against YF. YFV contains live-attenuated virus, and is contraindicated in patients treated with immunosuppressive drugs. Following vaccination, the patient fell ill with influenza-like illness. Elevated transaminase levels and YF viremia were detected. Despite being immunocompromised, the patient did not develop more severe adverse effects. Neutralising antibodies to YF virus were detected on day 14 following vaccination and remained protective at least 10 months after vaccination. Limited data is available on outcomes of YFV in patients receiving immunosuppressive therapy, including biologics, and we report this case as a reminder of vigilance of vaccine recommendations in this population.


Assuntos
Doença de Crohn/tratamento farmacológico , Imunossupressores/uso terapêutico , Infliximab/uso terapêutico , Erros Médicos , Metotrexato/uso terapêutico , Vacinação/efeitos adversos , Febre Amarela/prevenção & controle , Contraindicações , Doença de Crohn/imunologia , Feminino , Humanos , Pessoa de Meia-Idade , Prognóstico , Viremia/diagnóstico , Febre Amarela/diagnóstico
17.
Emerg Microbes Infect ; 5(7): e69, 2016 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-27406389

RESUMO

Yellow fever (YF) is a viral disease endemic to the tropical regions of Africa and South America. An outbreak of YF has been occurring in Angola, since the beginning of 2016. In March 2016, a 32-year-old Chinese man who returned from Angola was hospitalized and diagnosed with the first case of imported YF in China. Clinical observations, blood viral RNA detection, serological testing and treatments for the patient were performed daily. The virus was isolated in Vero cells, and the complete viral genome was sequenced and analyzed using the next-generation genomic sequencing platform. The patient presented with hemorrhagic fever, jaundice and oliguria at day 3 after onset, which rapidly progressed to multisystem organ failure with extremely elevated liver, pancreatic and myocardial enzymes. The patient died despite the intensive supportive treatments that were performed. A liver biopsy showed severe and multilobular necrosis. Viral RNA was detectable throughout the clinical course of the disease. Whole-genomic sequence analysis revealed that the virus belongs to the Angola71 genotype. Although the virus has been circulating in Angola for 45 years, only 14 amino-acid substitutions and no amino-acid changes were observed in the membrane and envelope proteins compared with the virus collected in 1971. The presence of this imported YF case in China indicated that with the increase in business travel among countries, YF outbreaks in Africa can lead to the international spread of the disease. The production and use of YF vaccines is, therefore, an urgent issue.


Assuntos
Viagem , Febre Amarela , Adulto , Angola/epidemiologia , Animais , Sequência de Bases , China , Chlorocebus aethiops , Surtos de Doenças , Evolução Fatal , Genoma Viral , Genótipo , Humanos , Fígado/patologia , Fígado/virologia , Masculino , Insuficiência de Múltiplos Órgãos/etiologia , Oligúria , RNA Viral/sangue , Análise de Sequência de DNA , Células Vero , Febre Amarela/diagnóstico , Febre Amarela/virologia , Vírus da Febre Amarela/genética , Vírus da Febre Amarela/isolamento & purificação
18.
Clin Vaccine Immunol ; 23(8): 689-97, 2016 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-27307452

RESUMO

Yellow fever (YF) is an acute hemorrhagic viral infection transmitted by mosquitoes in Africa and South America. The major challenge in YF disease detection and confirmation of outbreaks in Africa is the limited availability of reference laboratories and the persistent lack of access to diagnostic tests. We used wild-type YF virus sequences to generate recombinant envelope protein in an Escherichia coli expression system. Both the recombinant protein and sucrose gradient-purified YF vaccine virus 17D (YF-17D) were used to immunize BALB/c mice to generate monoclonal antibodies (MAbs). Eight MAbs were established and systematically characterized by indirect enzyme-linked immunosorbent assay (ELISA), Western blot analysis, and immunofluorescence assay (IFA). The established MAbs showed strong reactivity with wild-type YF virus and recombinant protein with no detectable cross-reactivity to dengue virus or Japanese encephalitis virus. Epitope mapping showed strong binding of three MAbs to amino acid positions 1 to 51, while two MAbs mapped to amino acid positions 52 to 135 of the envelope protein. The remaining three MAbs did not show reactivity to envelope fragments. The established MAbs exert no neutralization against wild-type YF and 17D viruses (titer of <10 for both strains). The applicability of MAbs 8H3 and 3F4 was further evaluated using IgM capture ELISA. A total of 49 serum samples were analyzed, among which 12 positive patient and vaccinee samples were correctly identified. Using serum samples that were 2-fold serially diluted, the IgM capture ELISA was able to detect all YF-positive samples. Furthermore, MAb-based antigen detection ELISA enabled the detection of virus in culture supernatants containing titers of about 1,000 focus-forming units.


Assuntos
Anticorpos Monoclonais/isolamento & purificação , Anticorpos Antivirais/isolamento & purificação , Antígenos Virais/análise , Testes Diagnósticos de Rotina/métodos , Ensaio de Imunoadsorção Enzimática/métodos , Febre Amarela/diagnóstico , Vírus da Febre Amarela/imunologia , Animais , Anticorpos Monoclonais/imunologia , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Escherichia coli/genética , Escherichia coli/metabolismo , Humanos , Imunoglobulina M/sangue , Fatores Imunológicos , Camundongos Endogâmicos BALB C , Ligação Proteica , Proteínas Recombinantes/genética , Proteínas Recombinantes/imunologia , Proteínas do Envelope Viral/genética , Proteínas do Envelope Viral/imunologia
19.
Rev. Soc. Bras. Med. Trop ; 46(4): 522-524, Jul-Aug/2013. graf
Artigo em Inglês | LILACS | ID: lil-683326

RESUMO

Sylvatic yellow fever is a zoonosis associated mainly with wild animals, especially those in the genus Alouatta, that act as the source of infection. Once infected, these animals pass the disease on to humans by way of an infected mosquito belonging to the genera Aedes, Haemagogus, or Sabethes. The present study is the first report of a case of yellow fever in non-human primates (NHP) in the State of Paraná, Brazil. After the case was diagnosed, several prophylactic measures were adopted to prevent outbreaks of the disease in humans.


Assuntos
Animais , Masculino , Alouatta/virologia , Doenças dos Macacos/diagnóstico , Febre Amarela/veterinária , Anticorpos Antivirais/sangue , Brasil , Imuno-Histoquímica/veterinária , Febre Amarela/diagnóstico , Vírus da Febre Amarela/imunologia
20.
Bol. venez. infectol ; 24(1): 39-47, ene.-jun. 2013.
Artigo em Espanhol | LILACS | ID: lil-721091

RESUMO

La fiebre amarilla representa a una de las fiebres hemorrágicas que adquieren en Venezuela y a una de las cuatro arbovirosis endémicas que tenemos. Revisando la literatura médica nacional e internacional, se actualizan aspectos relevantes de esta endemia rural. Se mencionan en la etiología las características del agente viral, que tiene ARN como componente primordial de su genoma. En la epidemiología, se menciona su prevalencia en el continente americano y africano y se evalúa su modo de transmisión. En la patogenia y la anatomía patológica se describe al hígado como órgano blanco de la infección. Se destacan en las manifestaciones clínicas los trastornos hemorrágicos y de la coagulación sanguínea. El diagnóstico como en Medicina Tropical, corresponde a un diagnóstico integral: la clínica, en primer lugar, asociada a la epidemiología y a la etiología de la enfermedad. Se establece diagnóstico diferencial con otras entidades relacionadas. El tratamiento es de soporte y en terapia intensiva. Se concluye con la profilaxis, evaluando la utilidad que sigue teniendo la vacunación.


The yelow fever represents one of the hemorrhagic fever that can be acquired in Venezuela and one of the four endemic arbovirosis we have. By reviewing the national and international medical literature. Relevant aspects of this endemic rural disease have been updated. In the etiology, several characterictics of the virus are mentioned; including the RNA as a primordial component of its genome. In the epidemiology, its prevalence on the African and American continents is mentioned, and the transmission mode es evaluated. In the pathogenesis and pathological anatomy, the liver is described as the primary organ of infection. Bleeding and blood clotting disorders are the essential clinical manifestations. Like in Tropical Medicina, The corresponding integral diagnosis is required. In the first instance, the clinical aspects, associated to the epidemiology and to the etiology of the disease are analyzed a diffential diagnosis is made with other related entities. The treatment consists of support measures and Intensive Care in the Intensive Care Unit (ICU). For the prophylaxis, we discuss the advantages of vaccination.


Assuntos
Humanos , Masculino , Feminino , Febre Amarela/complicações , Febre Amarela/diagnóstico , Febre Amarela/epidemiologia , Vacina contra Febre Amarela/administração & dosagem , Doenças Transmissíveis/complicações , Doenças Transmissíveis/tratamento farmacológico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA